TY - JOUR T1 - Early start of oral clarithromycin is associated with better outcome in COVID-19 of moderate severity: the ACHIEVE open-label trial JF - medRxiv DO - 10.1101/2020.12.22.20248753 SP - 2020.12.22.20248753 AU - Konstantinos Tsiakos AU - Antonios Tsakiris AU - Georgios Tsibris AU - Pantazis Voutsinas AU - Periklis Panagopoulos AU - Maria Kosmidou AU - Vasileios Petrakis AU - Areti Gravvani AU - Theologia Gkavogianni AU - Eleftherios Klouras AU - Konstantina Katrini AU - Panagiotis Koufargyris AU - Iro Rapti AU - Athanassios Karageorgos AU - Emmanouil Vrentzos AU - Christina Damoulari AU - Vagia Zarkada AU - Chrysanthi Sidiropoulou AU - Sofia Artemi AU - Anastasios Ioannidis AU - Androniki Papapostolou AU - Evangelos Michelakis AU - Maria Georgiopoulou AU - Dimitra-Melia Myrodia AU - Panteleimon Tsiamalos AU - Konstantinos Syrigos AU - George Chrysos AU - Thomas Nitsotolis AU - Haralampos Milionis AU - Garyphallia Poulakou AU - Evangelos J. Giamarellos-Bourboulis Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/02/10/2020.12.22.20248753.abstract N2 - Background To study the efficacy of oral clarithromycin in moderate COVID-19.Methods An open-label non-randomized trial in 90 patients with COVID-19 of moderate severity was conducted between May and October 2020. The primary endpoint was defined at the end-of-treatment (EOT) as no need for hospital re-admission and no progression into lower respiratory tract infection (LRTI) for patients with upper respiratory tract infection; and as at least 50% decrease of the respiratory symptoms score the without progression into severe respiratory failure (SRF) for patients with LRTI. Viral load, biomarkers, the function of mononuclear cells, and safety were assessed.Results The primary endpoint was attained in 86.7% of patients treated with clarithromycin (95% CIs 78.1-92.2%); this was 91.7% and 81.4% among patients starting clarithromycin the first 5 days from symptoms onset or later (odds ratio after multivariate analysis 6.62; p: 0.030). The responses were better for patients infected by non-B1.1 variants. Clarithromycin use was associated with decreases in circulating C-reactive protein, tumour necrosis factor-alpha and interleukin (IL)-6; by increase of Th1 to Th2 mononuclear responses; and by suppression of SARS-CoV-2 viral load. No safety concerns were reported.Conclusions Early clarithromycin treatment provides most of clinical improvement in moderate COVID-19 (Trial Registration: ClinicalTrials.gov, NCT04398004)Competing Interest StatementP. Panagopoulos has received honoraria from GILEAD Sciences, Janssen, and MSD. G. Poulakou has received independent educational grants from Pfizer, MSD, Angelini, and Biorad. H. Milionis reports receiving honoraria, consulting fees and non-financial support from healthcare companies, including Amgen, Angelini, Bayer, Mylan, MSD, Pfizer, and Servier. E.J. Giamarellos-Bourboulis has received honoraria from Abbott CH, Angelini Italy, InflaRx GmbH, MSD Greece, XBiotech Inc., and BRAHMS GmbH (Thermo Fisher Scientific); independent educational grants from AbbVie Inc, Abbott CH, Astellas Pharma Europe, AxisShield, bioMerieux Inc, Novartis, InflaRx GmbH, and XBiotech Inc; and funding from the FrameWork 7 program HemoSpec (granted to the National and Kapodistrian University of Athens), the Horizon2020 Marie-Curie Project European Sepsis Academy (granted to the National and Kapodistrian University of Athens), and the Horizon 2020 European Grant ImmunoSep (granted to the Hellenic Institute for the Study of Sepsis). The other authors do not report any conflict of interest.Clinical TrialNCT04398004Funding StatementThe study was funded by Abbott Product Operations AG.Funding bodies had no role in the design, conduct, analysis and interpretation of data, and decision to publish.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:EudraCT number 2020-001882-36; National Ethics Committee approval 45/20; National Organization for Medicines approval ISO 36/20; ClinicalTrials.gov registration NCT04398004. Collection of data from concurrent comparators was approved by the Ethics Committees of AHEPA Thessaloniki General Hospital; ATTIKON University General Hospital; Patras University General Hospital; and Sotiria Athens General HospitalAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDate are available from the corresponding author on request. ER -